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INVESTIGATING BRAIN STRUCTURAL DIFFERENCES AND THE IMPACT 
OF COMMON GENETIC VARIATION ACROSS THE PSYCHOSIS SPECTRUM 
 
LEIGHANNE Q. ORMSTON 
ABSTRACT 
Background: 
Abnormalities in glutamate transmission have been implicated in schizophrenia 
(SZ). A genome-wide association study (GWAS) associated single nucleotide 
polymorphisms (SNPs) in glutamate-related genes with the disorder. To elucidate a 
pathologic role of these variants, this study aims to examine the effects of these SNPs on 
hippocampal volume. 
Method:   
Six SNPs from five glutamate-related genes identified by the Psychiatric Genetics 
Consortium were selected in 279 controls and 284 probands recruited from the B-SNIP 
study. Hippocampal subfield volumes were extracted from T1 weighted images via the 
MAGeT pipeline. A mixed model analysis was conducted using SPSS to evaluate a 
diagnosis by SNP effect on volumes, with site as a random factor, age, sex, and principal 
component analysis values as fixed factors. P values were adjusted for multiple 
corrections. 
Results:   
rs10520163 (CLCN3), rs2973155 (GRIA1), and rs9922678 (GRIN2A) displayed 
a significant main effect (p< .01) on bilateral total hippocampal volume. Post hoc 
		 vi 
comparison revealed individuals homozygous for the risk allele (HZ-Risk) had 
significantly smaller volumes than those who were homozygous for the non-risk allele 
(HZ-NoRisk) (p<.01). For the same SNPs, a significant diagnosis-by-genotype 
interaction (p<.01) was found for bilateral total hippocampal volume. Significant main 
effects (p<.01) for the same SNPs were found in subfield volumes bilaterally for the 
CA1, subiculum, and stratum, with HZ-Risk having smaller volumes. 
Conclusion:  
 Our findings suggest CLCN3, GRIA1, and GRIN2A appear to be associated with 
reductions in bilateral hippocampal total volume and subfield regions, indicating a 
potential mechanism by which these genes may confer risk for the disorder. 
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INTRODUCTION 
 
Schizophrenia is a complex, multi-faceted psychiatric disorder with a lifetime 
prevalence of approximately 1% and an estimated heritability as high as 80% (Ripke et 
al., 2014; Ohi, Shimada, Yasuyama, Uehara, & Kawasaki, 2016). A majority of 
symptoms can be divided into two categories, positive and negative. Positive symptoms 
include delusions, hallucinations, and thought disorganization, while negative symptoms 
can comprise of a lack of emotion and motivation, and poor social function (Lewis & 
Lieberman, 2000). In addition, patients often demonstrate dysfunction in cognitive 
domains such as attention, memory, and executive functioning (Keshavan, Eack, Prasad, 
Haller, & Cho, 2017). Though an extensive volume of literature on proposed etiologies 
and pathologies of the disorder exists, the specific factors that cause schizophrenia 
remain unknown.  
 Despite an unknown cause, the risk and heritability of schizophrenia are 
reasonably well-documented in the literature. Biological relatedness plays a large role in 
determining the risk of developing schizophrenia, with first-degree relatives of affected 
individuals having a higher risk of illness manifestation compared to second-degree 
relatives (Lewis & Levitt, 2002). Studies of heritability (the proportion of differences 
within a trait that is due to genetic variability within a given population (Schwab & 
Wildenauer, 2013)) have examined the rates of incidence of schizophrenia amongst 
relatives, including in twin and adoption studies. In a review of five separate studies 
conducted between 1996 and 1999, research showed concordance rates of schizophrenia 
	2 
of up to 65% in monozygotic twins, and as high as 28% in dizygotic twins (Cardno & 
Gottesman, 2000). In addition, further studies examined biological children of individuals 
with schizophrenia who were adopted. Researchers concluded that the risk of developing 
schizophrenia remained higher in the children with schizophrenic biological parents than 
those children who were adopted from the healthy control families (Kety, Rosenthal, 
Wender, & Schulsinger, 1971; Kety et al., 1994). Current advancements in molecular 
technology allow the potential for even more insight into the role of genetics in 
schizophrenia. High heritability of the disorder suggests that an endophenotype-approach 
may be suitable for further characterizing genetic influences on certain aspects of 
schizophrenia.   
 
The Endophenotype Approach 
John and Lewis first described the concept of an endophenotype in 1966, with the 
distinction between an “endophenotype” and an “exophenotype” being made, albeit in the 
context of insects. An endophenotype, sometimes known as an intermediate phenotype, 
was specifically described as a trait “discoverable by a biochemical test or microscopic 
examination” (John & Lewis, 1966). However, the theory has since evolved and been 
applied to the study of human disease, including psychiatric illness. Endophenotype-
based approaches are commonly used in conjunction with genetic studies in order to help 
connect distinct clinical phenotypes with certain genotypes (Gottesman & Gould, 2003). 
The following parameters have been suggested when attempting to identify an 
endophenotype related to psychiatric genetics; the endophenotype must be: a) associated 
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with illness in the population, b) heritable, c) state-independent, d) co-segregated with 
illness within families, and e) found in non-affected family members at a higher rate than 
the general population (Gottesman & Gould, 2003). Endophenotypes may help bridge the 
gap between genes and behavior by identifying certain symptomatology that occurs 
consistently in the disease. When examining individuals with schizophrenia, certain traits 
have emerged as candidate endophenotypes of the disorder, including brain structure.  
Brain structural abnormalities have been consistently identified across various 
neuroimaging modalities in individuals with schizophrenia. In a study conducted by 
Prasad & Keshavan in 2008, magnetic resonance imaging (MRI) morphometric measures 
were examined to determine if they qualified as a suitable endophenotype measure for 
schizophrenia. Though the study acknowledged that morphometric measures did not meet 
all criteria (i.e. not enough evidence to support these measures as being state-
independent), they did meet the majority of criteria described (Prasad & Keshavan, 
2008). The study found that these brain structural measures met several criteria of 
endophenotypes, including that they were a) consistently associated and specific to 
schizophrenia, b) present in unaffected relatives and co-segregated with the disorder, and 
c) moderately to highly heritable and quantifiable (Prasad & Keshavan, 2008). 
Furthermore, these measures were found to co-vary with the broad psychopathology of 
the disease itself, and were found to have some variations thought to probabilistically 
predict the disease (Prasad & Keshavan, 2008). Brain structure differences have been 
associated with genetic influences as well, further strengthening its candidacy as an 
endophenotype for schizophrenia and leading to the expansion of the field of 
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schizophrenia imaging genetics and genomics. Imaging genetics and genomics originally 
emerged as an attempt to characterize genetic influences on the brain, with the goal of 
identifying neural mechanisms through which genetic and molecular differences impact 
cognition, emotion, and behavior in disease (Bogdan et al., 2017). In regards to patients 
with schizophrenia, the hippocampus has been an attractive region of the brain for 
researchers attempting to distinguish the impact of these certain genetic and molecular 
differences (Adriano, Caltagirone, & Spalleta, 2012; Mathew et al., 2014; Tamminga, 
Stan, & Wagner, 2010).   
 
The Hippocampus  
The hippocampus has been an area extensively studied in regards to 
schizophrenia. Located inside the medial temporal lobe (MTL) of the brain, the 
hippocampus, or hippocampal formation, consists of several subregions including the 
subiculum, the dentate gyrus, and the cornu ammonis (CA) fields (Adriano et al., 2012). 
The rest of the MTL consists of the perirhinal, parahippocampal, and entorhinal cortices 
(Mathew et al., 2014). The perirhinal and parahippocampal cortices receive input from 
the neocortex and project to the entorhinal cortex (Tamminga et al., 2010). From the 
entorhinal cortex (EC), projections extend to the hippocampus through either the 
performant pathway to the dentate gyrus (where they will eventually progress to the CA3 
and CA1), or via direct projections to the CA3 and CA1 subfields (Tamminga et al., 
2010).  
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The hippocampus has widespread roles in the brain involving memory, 
specifically declarative memory, and cognition, with individual subfields having distinct 
functions in each process. Working in conjunction with the neocortex, the hippocampus 
plays a key role in the encoding and retrieval of memory (Adriano et al., 2012; Mathew et 
al., 2014). It is thought to bind input from the neocortex through conjunctive encoding, 
where the features of an event are bound into a memory trace. Furthermore, it then has 
the ability to retrieve the stored input patterns, which allows for recognition, inferential 
reasoning, and event recollection through pattern completion (Tamminga et al., 2010).  
Each subfield of the hippocampus is responsible for different aspects of this 
complex process. The dentate gyrus (DG)/CA4 subregion has been linked to pattern 
separation and classification of new events, regardless of if they are similar or different to 
previous events, as unique (Adriano et al., 2012). The CA3 region has been shown to 
demonstrate a supportive role in this process (Tamminga, Southcott, Sacco, Wagner, & 
Ghose, 2012), in addition to playing a role in conjunctive encoding and pattern 
recognition (Adriano et al., 2012; Hunsaker & Kesner, 2008). While work on the 
DG/CA4 and CA3 has been widespread, the role of the CA2 was previously not as well 
explored. However, recent studies have suggested that the CA2 subregion plays a role in 
both synaptic plasticity and social memory (Dudek, Alexander, & Farris, 2016; Hitti & 
Siegelbaum, 2014; Stevenson & Caldwell, 2014). Additionally, multiple studies on the 
CA1 have suggested a role in the temporal processing of visual objects (Hoge & Kesner, 
2007; Hunsaker & Kesner, 2008). Finally, the subiculum has been considered part of the 
“output region” of the hippocampus, a function that, when not working properly, may 
	6 
lead to psychosis (Tamminga et al., 2010; Mathew et al., 2014). The subiculum is also a 
main relay point for neurons in the CA1. Interestingly smaller subicula have been 
observed in patients at familial high risk for developing schizophrenia (Francis et al., 
2013). As mentioned above, information flows through the hippocampus in a trisynaptic 
pathway that is glutamate dependent and unidirectional, from the entorhinal cortex to the 
dentate gyrus, to the CA3, to the CA1, and finally to the subiculum (Tamminga et al., 
2012; Tamminga et al., 2010; Heckers & Konradi, 2010). Direct projects from the 
entorhinal cortex also exist and extend directly to the subfields (Tamminga et al., 2012; 
Tamminga et al., 2010; Heckers & Konradi, 2010). When working properly, the 
hippocampus plays a complex, efficient role in the memory formation and consolidation 
process. Unsurprisingly, dysfunction of the hippocampus can lead to severe deficits on 
subfield and overall brain structure and function, and cognitive ability. Such effects have 
been well-documented in patients with schizophrenia.   
 
The Hippocampus and Schizophrenia  
Models of hippocampal pathology and its relation to schizophrenia are widespread 
and multimodal. Heckers and Kondradi (2017) describe five models of hippocampal 
dysfunction and its effects on schizophrenia, including the hippocampus’ potential role in 
psychosis, memory deficits, connectivity to cortices, and neurotransmission with 
glutamate and GABA. Many studies combine these models together when examining 
schizophrenia. Mathew et al. (2014) reported that psychosis itself is theorized to be the 
result of hippocampal inadequacy and the inability to discriminate between present and 
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past memory experiences. Consequently, multiple aspects of the hippocampus have been 
examined in schizophrenia. Tamminga, Stan, & Warner suggest four key pathological 
features of the hippocampus in schizophrenia: 1) a consistent reduction in hippocampal 
volume, 2) an increase in perfusion, 3) a lack of activation during declarative memory 
tasks that are dependent on conjunctive representations, and 4) a decrease in dentate 
gyrus neurogenesis and signaling from dentate gyrus granule cells (Tamminga et al., 
2010). Differences in hippocampal brain volume remain some of the most consistently 
reported imaging findings in schizophrenia, across the spectrum of disease and as a 
result, will be examined in this study.   
 
The Hippocampus and Schizophrenia: Hippocampal Volume 
Alterations in hippocampal volume can be considered a hallmark feature of 
schizophrenia. Studies across all stages of schizophrenia, including first episode 
psychosis and schizophrenia patients (Narr et al., 2004; Wood et al., 2001; Velakoulis, 
Wong, Yung, Brewer, & Pantelis, 2006; Adriano et al., 2012, Szeszko et al., 2003), and 
those with chronic schizophrenia (Velakoulis et al., 2006; van Erp et al., 2016; Kraguljac, 
White, Reid, & Lahti, 2013; Arnold et al., 2015) have all demonstrated decreased 
hippocampal volume. Similar findings have also been found in the relatives of patients 
and those at increased risk for the disorder (Tepest, Wang, Miller, Falkai, & Cseransky, 
2003; Phillips et al., 2002; Velakoulis et al., 2006; Witthaus et al., 2010). The presence of 
reduced hippocampal volume across the schizophrenia spectrum, particularly in first 
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episode patients and those at high risk for the disorder, is important to examine closely, 
as it strengthens its candidacy as an endophenotype.  
 
Hippocampal Volume – First Episode Patients  
A meta-analysis performed by Adriano et al., in 2012 examined studies that 
looked at hippocampal volume in first episode patients and found that the hippocampal 
volume reduction found in chronic patients was also present in first-episode patients. This 
finding echoed a previous study that showed similar rate of hippocampal volume loss 
between patients with first-episode psychosis and those with chronic schizophrenia 
(Wood et al., 2001). Bilateral reductions in hippocampal volume in first episode have 
been found in several studies (Narr et al., 2004, Phillips et al., 2002; Szeszko et al., 2003; 
Adriano et al., 2012); however, some studies have only demonstrated unilateral 
reductions in volume (Velakoulis et al., 2006). The mechanism for these volume 
reductions is unclear, both biologically and chronologically, as studies have also 
demonstrated reduced volume in unaffected relatives and those at high risk for the 
disorder.  
 
Hippocampal Volume – High Risk Individuals   
Studies examining individuals at high risk for the disorder have shown mixed 
results. A study in 2003 examined hippocampal brain volumes in three groups: 1) patients 
with schizophrenia and their unaffected siblings from families with multiple affected 
members and 2) patients with schizophrenia from families without another affected 
	9 
member, and 3) healthy controls. Findings showed decreased hippocampal volume in 
patients with schizophrenia from families with multiple affected members, a finding that 
was also present in their unaffected siblings (Tepest et al., 2003). These findings matched 
later studies in 2002 and 2006 where reductions in hippocampal volume in ultra-high-risk 
(UHR) patients were found compared to healthy controls (Phillips et al., 2002; Witthaus 
et al., 2010). However, a study in 2006 failed to identify any change in hippocampal 
volume between UHR individuals and healthy controls (Velakoulis et al., 2006).  
 
Hippocampal Volume – Large Cohort Studies   
Although the above findings are somewhat mixed, hippocampal volume remains a 
focal point in brain structure studies in schizophrenia. Recent studies with large cohorts 
of participants have continued to show hippocampal volume reduction. The Bipolar-
Schizophrenia Network on Intermediate Phenotypes (B-SNIP) consortium examined 
hippocampal volume in a large cohort of 596 individuals with either schizophrenia, 
schizoaffective disorder, or bipolar disorder with psychosis and their first-degree 
relatives. Findings showed that individuals with schizophrenia and schizoaffective 
disorder had significantly lower hippocampal volumes compared to controls (Arnold et 
al., 2015). This finding was then replicated in a larger cohort in a study conducted 
through the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) 
consortium in 2016. Brain volumes of 2028 schizophrenia patients and 2540 healthy 
controls were examined, with patients being found to have significantly smaller 
hippocampal volumes (van Erp et al., 2016).  
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 In addition to total hippocampal volume reductions, specific subfield reductions 
have also been demonstrated in patients with schizophrenia. A previous study conducted 
through the B-SNIP consortium examined hippocampal subfield volume across the 
psychosis spectrum, including those with schizophrenia, schizoaffective disorder, and 
psychotic bipolar disorder. Findings showed reduced overall volume in all three 
diagnostic groups compared to healthy controls (Mathew et al., 2014). In addition, 
prominent reductions in the CA2/CA3 region of the hippocampus were found across all 
three groups. These findings were replicated in another study conducted in 2016 by 
Haukvik et al. In a cohort of 702 healthy controls and patients with either schizophrenia 
or bipolar disorder, reductions were found bilaterally in the CA2/3, CA4/DG, and 
subiculum in patients (Haukvik et al., 2016).  
It is clear that volume abnormalities in the hippocampus have been consistently 
reported across the literature. However, in addition to examining the role of abnormal 
hippocampal structure, much focus has been dedicated towards investigating atypical 
molecular mechanisms in the hippocampus. The neurotransmitters dopamine and 
glutamate have been heavily implicated in schizophrenia pathology, hypotheses that have 
evolved as research has advanced. Current research has examined the role of 
glutamatergic neurotransmission as a potential explanation for altered brain function in 
the hippocampus.   
 
The NMDA Receptor Hypofunction Hypothesis of Schizophrenia  
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The role of glutamate in schizophrenia has been investigated for decades, with 
reports of altered glutamate in patients with schizophrenia dating as far back as 1949 
(Kintzinger & Arnold, 1949). The original glutamate hypothesis focused on hypofunction 
of one of the ionotropic types of glutamate receptor, the N-methyl- D-aspartate (NMDA) 
receptor (NMDAR). Support for this hypothesis has come from a wealth of evidence, 
including biochemical and animal studies, and post mortem research.  
Studies implicated NMDA receptors as early as 1987. Researchers in multiple 
studies demonstrated that non-competitive antagonists of the NMDA receptor, including 
phencyclidine (PCP), dizocilpine (MK801), and ketamine, could elicit psychological 
effects, both positive and negative, that were similar to those found in patients with 
schizophrenia (Javitt, 1987; Krystal et al., 1994). This finding was replicated in rats the 
following year. Animals given NMDAR antagonists developed neurotoxic changes 
similar to those found in the brains of patients with schizophrenia (Olney & Farber, 
1995). The biochemical mechanisms of the NMDA receptor have continued to be studied 
extensively, with new research focusing specifically on regulation of this receptor 
through specific modulatory binding sites.  
Post mortem studies have also highlighted the importance of NMDARs. Early 
studies further implicated NMDARs, with researches finding reduced densities of the 
receptor in both the superior frontal (Sokolov, 1998) and the superior temporal cortex 
(Humphries, Mortimer, & Hirsch, 1996) of patients with schizophrenia. With the 
innovative molecular techniques, more recent post mortem studies have found the same 
reduced NMDAR densities, down to the mRNA and protein level (Weickert et al., 2013).  
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Since then, several studies have focused on eliciting specific pathologic 
mechanisms of NMDA receptors. Currently, immunologic and pharmacologic models of 
the disease are prevalent. Reviews of the literature have focused on theories such as the 
presence of anti-NMDA receptor antibodies in those with schizophrenia (Pollak, 
McCormack, Peakman, Nicholson, & David, 2013; Pearlman & Najjar, 2014), as well as 
using treatments targeted at NMDA receptors and receptor function to gain more insight 
into molecular mechanisms of the disease (Hashimoto, 2014; Tsai & Lin, 2010). As the 
research into NMDA receptors has expanded, the glutamate hypothesis has diversified. 
Research has evolved to focus on a model of glutamatergic dysregulation, rather than 
hypo- or hyperfunction of any single receptor. As Meador-Woodruff and Healy (2000) 
point out, disturbances in any of the glutamate receptors could produce the appearance of 
a dysfunctional NMDA receptor. Glutamate has several subtypes of receptors, other than 
the NMDA receptor, including a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors (AMPARs), which are the other type of ionotropic glutamate receptor 
(Coyle, Tsai, & Goff, 2003), and G-protein coupled metabotropic glutamate receptors 
(Meador-Woodruff & Healy, 2000). Therefore, a different approach to examining the role 
of glutamate in schizophrenia has been to investigate regional differences in glutamate 
neurotransmission and receptor location, across different receptors, as opposed to 
focusing on any single receptor.  
  
Glutamate and the Hippocampus  
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A large body of evidence has suggested that many types of glutamate receptors, 
including the aforementioned ionotropic AMPA and NMDA receptors, as well as the 
Group I, II, and III metabotropic glutamate receptors, are located throughout the 
hippocampus. AMPA and NMDA receptors are predominantly postsynaptic and are co-
localized throughout the hippocampus (Meador-Woodruff & Healy, 2000). Group I 
metabotropic receptors are reported as postsynaptic as well, while Group II and Group III 
receptors are considered to be pre-synaptic modulators of glutamate release (Meador-
Woodruff & Healy, 2000). Both ionotropic and metabotropic glutamate receptors play 
important, intertwined roles in producing both efficient and effective glutamatergic 
neurotransmission. For example, the activation of AMPA receptors is required in order to 
activate NMDA receptors (Meador-Woodruff & Healy, 2000; Coyle, 2006). 
Additionally, dysfunction of certain metabotropic glutamate receptors involved in the 
reuptake and recycling process can lead to decreased availability of glutamate, which in 
turn, can lead to hypoactivity of both AMPA and NMDA receptors (Meador-Woodruff & 
Healy, 2000). The actions of each receptor have important consequences on one another, 
which further strengthens the hypothesis that dysregulation of the glutamatergic 
neurotransmission process as a whole may be more central to schizophrenia pathology. 
Studies that report abnormalities in the distribution and function of each type of receptor 
in patients with schizophrenia further support this theory (Meador-Woodruff & Healy, 
2000; Coyle 2006). Reduced glutamatergic output from the hippocampus may be a 
suitable mechanism for the onset of psychosis and specific aspects of schizophrenia (Gao 
et al., 2000).  
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Interestingly, although many studies focus on hippocampal volume reductions in 
schizophrenia, and many studies focus on glutamate receptor hypofunction in 
schizophrenia, few studies examine both effects simultaneously. One study examined the 
effects of NMDA receptor hypofunction on hippocampal volume via a serine racemase 
knockout mouse model. Serine racemase is the enzyme responsible for generating D-
serine, a strong agonist of the glycine modulatory site on NMDA receptors. Mice without 
the serine racemase enzyme had decreased hippocampal volume versus those with the 
enzyme (Balu et al., 2013). Previous studies have demonstrated further effects differences 
in D-serine GMS binding can have on brain structure and function (Basu et al., 2009; 
DeVito et al., 2011) but have not examined the hippocampus specifically. The Balu et al. 
(2013) study suggests a tentative link between NMDA receptor hypofunction and 
hippocampal volume, but further research is needed to establish a more complete 
connection. As schizophrenia is highly heritable, it is therefore plausible that genetic 
variants implicated in NMDAR function and glutamate transmission may have an effect 
on hippocampal volume. Thus, a potential way to model the effects of glutamate receptor 
dysregulation and its effects on hippocampal volume is through imaging genetics studies.  
 
Genetics and Schizophrenia   
The high heritability rate of schizophrenia, as mentioned above, suggests the 
potential role of genetics in schizophrenia. A popular approach when attempting to 
explain the genetic link to schizophrenia susceptibility is the common disease-common 
allele (CDCA) hypothesis. The CDCA hypothesis suggests that the probability of disease 
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is increased due to multiple, commonly inherited alleles that each confer a weak to 
modest risk working together (Rodriguez-Murillo, Gogos, & Karayiorgou, 2012). High 
prevalence of the disorder is then thought to be explained by both reduced visibility of 
each allele to negative selection (due to individual small effect), and the assumption of 
occasional recombination into high risk combinations (Rodriguez-Murillo et al., 2012). 
Identification of these disease-causing alleles has become easier with new technological 
advances that allow researchers to efficiently sift through large amounts of genetic data in 
a relatively short amount of time.  
The advent of the genome-wide association study (GWAS), has allowed for 
potential identification of associations between genetic variants in a certain population 
sample, usually with the goal of better understanding the pathology of a specific disease 
or disorder (Visscher et al., 2017). One function of a GWAS is to examine genetic 
variations known as single nucleotide polymorphisms (SNPs). SNPs occur when there is 
a change in a single nucleotide of the DNA sequence and are one of the most common 
forms of genetic variation in humans. A SNP is considered to be associated with disease 
if it is significantly more frequent in affected individuals. GWASs are often used to 
compare two groups of DNA, one from the population with the disease in question, the 
other from a similar but unaffected population. With the advent of large SNP arrays, a 
person’s DNA can be examined for thousands of potentially disease-associated SNPs at 
one time. 
The Schizophrenia Working Group of the Psychiatric Genetics Consortium (PGC) 
conducted one of the largest schizophrenia GWAS to date, with a total of 36,989 cases 
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and 113,075 controls (Ripke et al., 2014). A total of 128 independent associations across 
108 loci were identified at genome significance, with 83 of them not having been 
previously reported. Several novel SNPs identified were related to glutamatergic 
neurotransmission, including SNPs within the following genes: CLCN3, GRIA1, GRM3, 
GRIN2A, SLC387A, and SRR. Though these variants have been demonstrated to be 
significantly associated with schizophrenia, it is not immediately apparent how they 
confer risk for the disorder. 
With heritability estimates of hippocampal volume estimated to be up to 70% 
(Hibar et al., 2016), it is not unreasonable to look towards a potential genetic link 
between schizophrenia risk genes and subsequent hippocampal volume. As demonstrated 
previously in mice, dysfunction in NMDA receptors can lead to decreases in 
hippocampal volume (Balu et al., 2013). GRIA1, GRM3, and GRIN2A can be thought of 
as structure genes, with each coding for either metabotropic or ionotropic glutamate 
receptors, and as mentioned previously, dysfunction in any could result in the same 
effects seen in NMDA receptor hypofunction studies (Ripke et al., 2014). CLCN3, 
SLC387A, and SRR play more functional roles in glutamatergic neurotransmission, 
including roles in calcium transport and glutamate reuptake (Ripke et al., 2014). 
Dysfunction in any of these functions could also lead to abnormal glutamate signaling 
processes and subsequent abnormalities in hippocampal volume. Investigation of the 
effect of these SNPs, outlined in Table 1, may provide a valuable opportunity to further 
characterize the effects of glutamatergic receptor dysfunction on hippocampal brain 
structure, specifically volume.  
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Specific Aims 
In this study, we have attempted to characterize the effects of six glutamate-
related SNPs identified by the PGC GWAS, outlined in Table 1. We will investigate the 
individual effects of these SNPs on total bilateral hippocampal volumes and subfield 
volumes in both healthy controls and patients with schizophrenia or schizoaffective 
disorder. Following examination of individual effects, we will examine the combined 
effects of each SNP by creating a polygenic risk score, in an attempt to determine the 
cumulative effects of each polymorphism on hippocampal volume in both healthy 
controls and patients. We hypothesize that individuals homozygous with a risk allele will 
display smaller hippocampal volumes than those heterozygous or homozygous for the 
non-risk allele. In addition, we expect individuals with a higher PGRS score to have 
smaller volumes, due to their increased loading of risk alleles. Such an investigation will 
have an important impact on our understanding of both the role of glutamate and 
hippocampal volume in schizophrenia and the underlying pathophysiological 
mechanisms of GWAS-identified variants. 
 
TABLE 1: Glutamate-relevant single nucleotide polymorphisms  
   SNP Gene Chromosome GWAS 
Ranking 
Minor 
Allele 
Major 
Allele 
Risk 
Allele 
SNP1 rs10520163 CLCN3 4 59 C T T 
SNP2 rs2973155 LINC01470 
GRIA1 
5 45 T C T 
SNP3 rs12522290 LINC01470 
GRIA1 
5 100 G C C 
SNP4 rs12704290 GRM3 7 48 A G A 
SNP5 rs9922678 GRIN2A 16 90 A G A 
SNP6 rs12325245 SLC387A 16 98 T A A 
	18 
METHODS  
 
Participants and Demographics  
Participants were recruited through a National Institute of Mental Health (NIMH) 
funded study: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). 
Participants were recruited from six sites (Wayne State University, Harvard University, 
Maryland Psychiatric Research Center, University of Chicago/University of Illinois at 
Chicago, University of Texas Southwestern Medical Center at Dallas, and the Institute of 
Living/Yale University).  
This study included a final total of 563 participants (133 male, 146 female), 
including 279 healthy controls (HC) and 284 probands (PB), with a diagnosis of either 
SZ (n = 173) or SZA (n = 111). Diagnoses were made based on the Structured Clinical 
Interview for DSM-IV Axis I Disorders (First, Spitzer, Gibbon, & Williams, 1995). 
Inclusion criteria for probands included the following: 1) age 15-65; 2) sufficient 
proficiency in English at the sixth-grade level or higher; 3) no significant neurologic 
disorders including those secondary to head injury; 4) no history of substance abuse 
within the last month or substance dependence within the last six months; and 5) negative 
urine toxicology screening results on the day of testing.  
Healthy were subject to the following additional criteria: 1) no personal or family 
history (first degree) of psychotic or bipolar disorders; 2) no personal history of recurrent 
mood disorder; 3) no lifetime history of substance dependence; and 4) no history of any 
significant cluster A Axis II personality features defined by meeting full criteria or within 
	19 
1 criterion of cluster A diagnosis of the Structured Interview for DSM-IV personality 
(Pfohl, Blum, & Zimmermann, 1997).  
Institutional review boards at each of the sites approved the study, and all sites 
use identical diagnostic, clinical, and recruitment techniques (Skudlarski et al., 2013).  
 
Structural Magnetic Resonance Imaging and Hippocampal Volume Acquisition 
 Scans were obtained across six sites with the following scanners at each site: 
Boston (3.0T, GE Signa); Detroit (3.0T, Siemens Allegra); Baltimore (3.0T, Siemens 
Trio tim); Hartford (3.0T, Siemens Allegra); Dallas (3.0T, Phillips); and Chicago (3.0T, 
GE Signa). The Alzheimer’s Disease Neuroimaging Initiative (ADNI) protocol 
(https://www.loni.ucla.edu/ADNI) was used to obtain high-resolution isotropic T1-
weighted MPRAGE scans (TR=6.7 msec, TE=3.1 msec, 8° flip angle, 256x240 matrix 
size, total scan duration=10:52.6 minutes, 170 sagittal slices, 1mm slice thickness, 
1x1x1.2mm3 voxel resolution).  
 Fully-automated segmentation of the hippocampus was generated via the Multiple 
Automatically Generated Templates (MAGeT) Brain algorithm (Pipitone et al., 2014; 
https://github.com/CobraLab/MAGeTbrain). In this technique (Pipitone et al., 2014; 
Treadway et al., 2015), a modest number of high-quality manually segmented atlases of 
the hippocampus and its subfields are used as input. These atlases are then matched to a 
subset of the participant dataset and a template library is generated. In this study, 21 
templates were used, a number that has been used in other studies using the same 
methodology (Pipitone et al., 2014; Guimond, Chakravarty, Bergeron-Gagnon, Patel, & 
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Lepage, 2016). Each subject is then nonlinearly warped to the subjects in the template 
library, and each label from the template library is warped to fit the subject. A total of 
105 candidate labels are generated and then fused together to create a final segmentation. 
Individual segmentations are then subject to rigorous quality control (QC). The total 
number of subjects scanned was 1,731, which included probands, healthy controls, and 
family members. After T1 and segmentation QC, 1,336 subjects were available, with 395 
subjects removed during the QC process.  After removing relatives, 722 subjects had both 
scan data and genetic data. After removing patients with bipolar disorder (n=159), there 
was a total of 563 participants. Our final sample size consisted of 279 healthy controls 
and 284 probands (schizophrenia = 173, schizoaffective disorder = 111).  
 
Genotype Acquisition and GWAS Analysis 
More information on genotype collection is described in detail in Alliey-
Rodriguez et al., 2017. The Illumina Infinium Psycharray (PsychChip), containing 
588,454 SNP markers including 50,000 specific genetic markers for neuropsychiatric 
disorders, was used to assess genotypes from blood DNA at the Broad Institute (Alliey-
Rodriguez et al., 2017). After QC and genotype imputation, the final imputed genotype 
set consisted of over 30 million autosomal markers, which was subsequently reduced 
down to 4,322,238 common variants.  
  Genetic analysis was conducted using PLINK 1.9 (Purcell et al., 2007). In the 
current study, genetic information was extracted for the six glutamate-related SNPs, 
(rs10520163, rs2973155, rs12522290, rs12704290, rs9922678, rs12325245) spanning 
	21 
across five genes (CLCN3, GRIA1, GRM3, GRIN2A, SLC387A). These 6 glutamate-
relevant SNPs were then used in our analysis.  
 
Statistical Analysis  
All statistics were conducted using a combination of IBM Statistical Package for 
Social Scientists (SPSS), Version 24 and the program R (https://www.R-project.org, 
Version 3.4.0). All p-values were corrected using Bonferroni correction for multiple 
comparisons.  
In order to account for population stratification, Principal Component Analysis 
(PCA) on the genotypes was conducted. The first two PCA eigenvectors captured the 
majority (< 75%) of ethnic-related variance and later were used as covariates in the 
mixed linear model in order to correct for population stratification.  
The main effect of genotype for each SNP on bilateral total hippocampal volume 
was first assessed using a mixed effects linear model, with age, sex, and the two PCA 
eigenvectors used as covariates. Site was entered as a random factor. SNP genotype, 
which consisted of either homozygous – risk (HZ-R), heterozygous (HET), or 
homozygous – no risk (HZ-NR), was used as a fixed factor. Total volume consisted of 
the sum of the following subfield volumes: CA1, subiculum, CA2/CA3, CA4/DG, and 
the stratum region (stratum radiatum, stratum lacunosum, and stratum moleculare). Right 
and left hemispheres were analyzed separately.  
We then looked for any interactions between phenotype (healthy control vs. 
probands) and genotype (HZ-R, HET, and HZ-NR). After establishing that an interaction 
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was present, post-hoc analysis was then conducted to determine what factor was 
responsible for the interaction. More specifically, post-hoc pairwise comparisons were 
conducted to determine whether differences of genotype within phenotype (ex. HZ-R vs. 
HZ-NR in healthy controls) or of phenotype within genotype (ex. HZ-R in healthy 
controls vs. HZ-R in probands) were significant.  
After determining which SNPs had significant effects on total hippocampal 
volume, those SNPs were then examined to determine their effects on hippocampal 
subfield volumes. The main effect of each SNP on hippocampal subfield volume was 
analyzed using the same mixed effects linear model with the same covariates, fixed 
factors, and random factor. Interactions were also examined for both genotype within 
phenotype and phenotype within genotype. The following subfields were examined 
independently for the right and left hemisphere: CA1, subiculum, CA2/CA3, CA4/DG, 
and the stratum region (stratum radiatum, stratum lacunosum, and stratum moleculare). 
As a final step, a polygenic risk score was constructed using odds ratio data from 
the PGC. All six SNPs were included. Polygenic risk scores (PGRS) were then formed 
using the “score” function in PLINK 1.9. This function performs the following steps: 1) 
multiplies the log of the odds ratio for a risk allele (per meta-analytic data) by the number 
of risk alleles carried by the individual subject (0, 1, or 2); 2) sums this across all risk 
alleles, and then 3) divides by the total number of SNPs to create a score (Padmanabhan 
et al., 2016; International Schizophrenia Consortium, 2009). After developing a PGRS 
for each participant, the effect of PGRS on bilateral hippocampal total volumes and 
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hippocampal subfield volumes was examined using another mixed effects linear model 
with the same covariates and factors mentioned above.  	  
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RESULTS 
 
 
Demographics  
Significant differences in mean age and sex were found between healthy controls 
and probands (Table 2). Subjects were recruited from the six sites mentioned above 
(Table 3).  
Genotypes were categorized into one of the following: homozygous for the risk 
allele (HZ-R), heterozygous, meaning the participant carried one risk allele and one 
normal allele (HET), or homozygous for the normal allele (HZ-NR). See Table 4 for 
genotype demographics. 
 
 
TABLE 2: Age and sex differences in healthy controls and probands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics Healthy 
Controls 
Probands p-value 
Mean Age 
 
38.14 35.70 0.02125 
(t = 2.31) 
Sex Male 133 164 0.02089 
(c2 = 5.3359)  Female 146 120 
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TABLE 3: Sample demographics. Note: CA=Caucasian, AA=African-American, 
OT=Oth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics Healthy 
Controls 
Probands Schizophrenia Schizoaffective 
N = 563 279 284 
 
173 111 
Age (mean) 38.14 35.70 35.47 36.07 
 
Sex Male 133 164 114 50 
 Female 146 120 59 61 
 
Race CA 177 134 76 58 
 AA 77 133 85 48 
 OT 25 17 12 5 
 
Site Dallas 63 56 19 37 
 Hartford 24 34 15 19 
 Baltimore 52 89 66 23 
 Chicago 62 51 30 21 
 Boston 38 14 9 5 
 Detroit 40 40 34 6 
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TABLE 4: Genotype demographics. Note: HZ-R = homozygous-risk genotype. HET = 
heterozygous genotype. HZ-NR = homozygous-no risk genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HZ-R HET HZ-
NR 
Missing F 
value/c2  
p-
value 
SNP1 
(rs10520163) 
T/T 
N=203 
T/C 
N=254 
C/C 
N=106 
 
 
N/A 
 
  
Mean Age  37.635 36.024 37.642 0.106 0.745 
Sex  
 
Male 105 134 58 0.250 0.882 
Female  98 120 48 
 
SNP2 
(rs2973155) 
T/T 
N=53 
T/C 
N=196 
C/C 
N=289 
N/A 
N=25 
  
Mean Age 36.434  35.995 37.640 36.640   1.456  
0.228 
Sex Male 36 103 147 11 5.280 0.071 
Female 17 93 142 14 
 
SNP3 
(rs12522290) 
C/C 
N=419 
G/C 
N=108 
G/G 
N=9 
N/A 
N=27 
  
Mean Age  36.802 37.935 27.556 37.593  0.156 0.693 
Sex Male 227 55 6 9 0.981 0.612 
Female 192 93 3 18 
 
SNP4 
(rs12704290) 
A/A 
N=3 
A/G 
N=63 
G/G 
N=473 
N/A 
N=24 
  
Mean Age 27.333 37.968 36.617 41.083  0.047 0.829 
Sex Male 2 34 248 13 0.289 0.865 
Female 1 29 225 11 
   
SNP5 
(rs9922678) 
A/A 
N=103 
A/G 
N=267 
G/G 
N=180 
N/A 
N=13 
  
Mean Age 38.913 36.180  36.872 36.538  1.068 0.302 
Sex Male 55 145 91 6 0.620 0.734 
Female 48 122 89 7 
   
SNP6 
(rs12325245) 
A/A 
N=397 
A/T 
N=123 
T/T 
N=9 
N/A 
N=34 
  
Mean Age 36.665 37.569  43.000 35.765  1.693 0.194 
Sex Male 218 62 4 13 1.081 0.582 
Female  179 61 5 21 
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Total Hippocampal Volume 
Main effect of genotype in all participants   
A significant main effect of genotype on total hippocampal volume was found bilaterally 
for rs10520163, rs2973155, and rs9922678 (Table 4). For rs10520163 and rs9922678, 
those with the HZ-R genotype were found to have significantly lower (p< 0.008, 
corrected) volumes than those with the HZ-NR genotype. Conversely, for rs2973155, 
those with the HZ-R genotype demonstrated significantly increased volumes compared to 
the HZ-NR genotype. In addition, rs9922678 showed significant differences between the 
HET and HZ-NR genotype, with individuals with the HET genotype having significantly 
lower left total volumes (p<0.008, corrected). 
 
TABLE 5: Main effect of genotype on mean hippocampal total volume. Note: all data 
was co-varied for age, sex, and principal component analysis values. 
HZ_R=homozygous-risk, HET=heterozygous, HZ_NR=homozygous no-risk. * indicates 
p<0.008 for Bonferroni correction for multiple comparisons. 1indicates combined volume 
of CA1, subiculum, CA2/CA3, CA4/DG, and stratum lacunosum, moleculare, and 
radiatum. 
 
 
RIGHT HEMISPHERE 
 Mean Total Volume1 (mm3) [standard 
error] 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
 HZ_R HET HZ_NR p-value p-value p-value 
SNP1 
(rs10520163) 
2312.221 
(31.301) 
2351.636 
(30.025) 
2417.110 
(15.054) 
.127 .001* .040 
SNP2 
(rs2973155) 
2455.527 
(44.148) 
2359.485 
(30.349) 
2325.151 
(28.336) 
.023 .002* .177 
SNP3 
(rs12522290) 
2337.572 
(28.173) 
2385.056 
(36.467) 
2494.414 
(95.321) 
.114 .093 .256 
SNP4 
(rs12704290) 
2484.370 
(162.296) 
2366.841 
(42.054) 
2344.117 
(26.871) 
.475 .384 .542 
SNP5 
(rs9922678) 
2293.317 
(34.688) 
2336.738 
(27.451) 
2400.195 
(29.695) 
.168 .002* .016 
SNP6 
(rs12325245) 
2351.549 
(27.346) 
2371.476 
(34.479) 
2403.144 
(95.365) 
.489 .582 .741 
	28 
 
Genotype by diagnosis interaction 
For the aforementioned SNPs, a significant diagnosis-by-genotype interaction was found 
bilaterally for total hippocampal volumes (p<0.008, corrected, see Table 6). These three 
SNPs were then included for post-hoc analysis.  
TABLE 6: Interaction – phenotype*genotype for total hippocampal volume. Note: all 
data was co-varied for age, sex, and principal component analysis values. Phenotype = 
healthy control or probands, genotype = HZ-R, HET, or HZ-NR. *indicates p<0.008 for 
Bonferroni correction for multiple comparisons. 
LEFT HEMISPHERE 
 Mean Total Volume1 (mm3) [standard 
error] 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
 HZ_R HET HZ_NR p-value p-value p-value 
SNP1 
(rs10520163) 
2262.079 
(27.334) 
2311.392 
(25.803) 
2379.849 
(33.457) 
.063 .001* .036 
SNP2 
(rs2973155) 
2404.097 
(42.266) 
2326.441 
(26.218) 
2273.682 
(23.662) 
.076 .002* .045 
SNP3 
(rs12522290) 
2295.291 
(23.393) 
2329.957 
(33.240) 
2522.622 
(95.950) 
.258 .017 .050 
SNP4 
(rs12704290) 
2523.485 
(165.462)  
2353.259 
(39.596) 
2296.296 
(21.564) 
.312 .169 .136 
SNP5 
(rs9922678) 
2237.332 
(31.780) 
2289.223 
(23.226) 
2369.235 
(25.993) 
.109 .000* .003* 
SNP6 
(rs12325245) 
2314.095 
(22.321) 
2304.548 
(31.041) 
2355.675 
(96.673) 
.747 .666 .604 
 RIGHT HEMISPHERE LEFT HEMISPHERE 
Interaction (Phenotype * 
Genotype) 
p-value F p-value F 
SNP1 
(rs10520163) 
.001* 4.276 .001* 4.030 
SNP2 
(rs2973155) 
.005* 3.349 .004* 3.466 
SNP3 
(rs12522290) 
.035 2.423 .037 2.391 
SNP4 
(rs12704290) 
.098 1.870 .047 2.261 
SNP5 
(rs9922678) 
.001* 4.304 .000* 4.637 
SNP6 
(rs12325245) 
.032 2.466 .093 1.898 
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Our post hoc-analysis revealed that within rs10520163, with healthy controls  
with HZ-R genotype having greater right total hippocampal volume than PB of the same 
genotype (p<.014, corrected) (Figure 1, Supplementary Table 1). Moreover, a significant 
genotype effect in rs10520163 and rs9922678 was also detected, specifically in healthy 
controls but not probands. For rs10520163, healthy controls with HET genotype had 
significantly lower right total volumes than those with the HZ-NR genotype (p<.008, 
corrected (Figure 1, Supplementary Table 2). In addition, for rs9922678 amongst healthy 
controls, those with the HZ-R genotype had significantly reduced bilateral total volumes 
(Figure 2) than those with the HZ-NR genotype (p<0.008, corrected). The rs10520163 
and rs9922678 had no significant effect on hippocampal volume in the probands group. 
Finally, while the interaction effect of rs2973155 was significant, no post-hoc analysis 
survived significance.  
 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
FIGURE 1: The genotype by diagnosis interaction on right total hippocampal volume for 
rs10520163. Note: data was co-varied for age, sex, and principal component analysis 
values. T/T = HZ-R, T/C = HET, C/C = HZ-NR. *indicates p<0.008 for Bonferroni 
correction for multiple comparisons. 
 
 
 
FIGURE 2: The effect of genotype within diagnosis on right total hippocampal volume 
for rs9922678. Note: data was co-varied for age, sex, and principal component analysis 
values. A/A = HZ-R, A/G = HET, G/G = HZ-NR. *indicates p<0.008 for Bonferroni 
correction for multiple comparisons. 
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FIGURE 1: The genotype by diagnosis interaction on right total hippocampal volume for 
rs10520163. Note: data was co-varied for age, sex, and principal component analysis 
values. T/T = HZ-R, T/C = HET, C/C = HZ-NR. *indicates p<0.008 for Bonferroni 
correction for multiple comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: The effect of genotype within diagnosis on right total hippocampal volume 
for rs9922678. Note: data w s co-varied for age, sex, and principal component analysis 
values. A/A = HZ-R, A/G = HET, G/G = HZ-NR. *indicates p<0.008 for Bonferroni 
correction for multiple comparisons. 
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FIGURE 1: The genotype by diagnosis interaction on right total hippocampal volume for 
rs10520163. Note: data was co-varied for age, sex, and principal component analysis 
values. T/T = HZ-R, T/C = HET, C/C = HZ-NR. *indicates p<0.008 for Bonferroni 
correction for multiple comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: The effect of genotype within diagnosis on right total hippocampal volume 
for rs9922678. Note: data was co-varied for age, sex, and principal component analysis 
values. A/A = HZ-R, A/G = HET, G/G = HZ-NR. *indicates p<0.008 for Bonferroni 
correction for multiple comparisons. 
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Hippocampal Subfield Volume 
 The SNPs that showed a significant main interaction effect (rs10520163, 
rs2973155, and rs9922678) were used for secondary analyses of hippocampal subfield 
volumes.  
 
rs10520163 – CLCN3 (SNP1) 
 Across all subjects, a significant main effect of genotype on subfield volume was 
found bilaterally for the CA1, subiculum, and stratum, as well as the left CA4/DG (Table 
7). For each of those regions, those with the HZ-R genotype had significantly lower 
volumes compared to individuals with the HZ-NR genotype (p<0.01, corrected). In 
addition, those with the HZ-R genotype showed significantly lower right subiculum 
volumes than those with the HET genotype (p<0.01, corrected).   
TABLE 7: Main effect of genotype on right and left hippocampal subfield volume for 
rs10520163. Note: all data was co-varied for age, sex, and principal component analysis 
values. 1 = stratum radiatum, stratum lacunosum, and stratum moleculare. *indicates 
p<0.01 for Bonferroni correction for multiple comparisons. 
 
rs10520163 – SNP1 
 Mean Volume (mm3) [standard 
error] 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
H_NR 
HZ_R HET HZ_NR p-value p-value p-value 
Right CA1 681.137 
(9.330) 
696.392 
(8.850) 
712.994 
(11.268) 
.078 .004* .120 
Right Subiculum 328.870 
(3.764) 
343.418 
(3.450) 
351.551 
(4.956) 
.001* .000* .140 
Right CA2/CA3 133.094 
(3.377) 
128.965 
(3.277) 
132.328 
(3.801) 
.083 .800 .252 
Right 
CA4/dentate 
gyrus 
607.792 
(10.314) 
610.668 
(10.013) 
630.007 
(11.587) 
.690 .016 .030 
Right stratum1 562.102 
(10.012) 
572.997 
(9.683) 
591.341 
(11.390) 
.142 .002* .045 
Left CA1 698.679 
(7.945) 
714.178 
(7.335) 
737.780 
(10.293) 
.087 .001* .034 
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Left Subiculum 313.322 
(3.672) 
323.555 
(3.390) 
329.216 
(4.755) 
.015 .003* .271 
Left CA2/CA3 138.631 
(2.859) 
138.479 
(2.749) 
141.798 
(3.315) 
.947 .278 .241 
Left CA4/dentate 
gyrus 
592.388 
(9.528) 
603.804 
(9.188) 
619.646 
(10.943) 
.121 .004* .081 
Left stratum1 519.653 
(8.411) 
532.228 
(8.032) 
552.256 
(9.961) 
.085 .000* .027 
 
Genotype by Diagnosis Interaction   
 Significant diagnosis-by-genotype interactions were found in both hemispheres 
(p<0.01, corrected, Table 8). For the right hemisphere, a significant interaction was found 
for the subiculum, CA4/DG, and stratum regions. For the left, significant interactions 
were observed for the CA1 and stratum.    
 
TABLE 8: Interaction – phenotype*genotype for right and left hippocampal subfield 
volume for rs10520163. Note: all data was co-varied for age, sex, and principal 
component analysis values. Phenotype = healthy control or probands, genotype = HZ-R, 
HET, or HZ-NR. *indicates p<0.01 for Bonferroni correction for multiple comparisons.1 
stratum refers to stratum radiatum, stratum lacunosum, and stratum moleculare. 
 
 
 
 
 
 
 
 
 
Right Hemisphere  
 p-value F 
CA1 .011 3.020 
Subiculum .001* 4.364 
CA2/CA3 .024 2.617 
CA4/Dentate gyrus .007* 3.232 
Stratum1 .000* 4.918 
Left Hemisphere 
 p-value F 
CA1 .002* 3.739 
Subiculum .059 2.146 
CA2/CA3 .079 1.983 
CA4/Dentate gyrus .016 2.812 
Stratum1 .000* 5.238 
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Post hoc-analysis revealed that healthy controls with the HZ-R had significantly 
higher volume in the right CA4/DG and stratum than probands with the same genotype 
(p<0.01, corrected, Figure 3A, Figure 3B, see Supplemental Table 3). In addition, healthy 
controls with the HZ-NR genotype had significantly higher volume in the bilateral 
stratum compared to probands (p<0.01, corrected, Figure 3B, Figure 4B). The CA1 did 
not demonstrate significant diagnosis effects within genotype.  
 
 
FIGURE 3: A. The effect of genotype by diagnosis interaction on right CA4/DG volume 
for rs10520163. B. The genotype by diagnosis interaction on right stratum volume for 
rs10520163. Note: data was co-varied for age, sex, and principal component analysis 
values. T/T = HZ-R, T/C = HET, C/C = HZ-NR. *indicates p<0.01 for Bonferroni 
correction for multiple comparisons. 
 
Moreover, while genotype did not affect the right subiculum and stratum in 
probands, healthy controls with the HZ-R genotype had smaller right subiculum volumes 
than those with the HZ-NR genotype (p<0.01, corrected, Figure 4A, see Supplemental 
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Table 4). In addition, healthy controls with the HET genotype had smaller right stratum 
volumes than those with the HZ-NR genotype (p<0.01, corrected, Figure 3B). For the left 
hemisphere, healthy controls with the HZ-R genotype and healthy controls with the HET 
genotype demonstrated significantly lower left stratum volumes than healthy controls 
with the HZ-NR genotype (p<0.01, corrected, Figure 4B). No genotype effects were 
detected within probands.  
 
FIGURE 4: A. The genotype by diagnosis interaction on right subiculum volume for 
rs10520163. B. The genotype by diagnosis interaction on left stratum volume for 
rs10520163. Note: data was co-varied for age, sex, and principal component analysis 
values. T/T = HZ-R, T/C = HET, C/C = HZ-NR. *indicates p<0.01 for Bonferroni 
correction for multiple comparisons. 
 
 
 
rs2973155 – GRIA1 (SNP2) 
 Across all subjects, a significant main effect of genotype on subfield volume was 
found bilaterally for the subiculum, CA2/CA3, and stratum, as well as the left CA1 
(Table 9). 
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TABLE 9: Main effect of genotype on right and left hippocampal subfield volume for 
rs2973155. Note: all data was co-varied for age, sex, and principal component analysis 
values. 1 = stratum radiatum, stratum lacunosum, and stratum moleculare. *indicates 
p<0.01 for Bonferroni correction for multiple comparisons. 
 
 
For each of those regions, participants with the HZ-R genotype had significantly 
higher volumes compared to individuals with the HZ-NR genotype (p<0.01, corrected). 
In addition, those with the HZ-R genotype showed significantly higher right CA2/CA3 
volumes than those with the HET genotype (p<0.01, corrected). Furthermore, participants 
with the HET genotype had higher right subiculum volumes than those with the HZ-NR 
genotype (p<0.01, corrected).  
 
rs2973155 – SNP2 
 Mean Volume (mm3) [standard error] HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
HZ_R HET HZ_NR p-value p-value p-value 
Right CA1 722.372 
(14.171) 
696.800 
(9.271) 
687.213 
(8.526) 
.071 .010 .259 
Right 
Subiculum 
356.321 
(6.725) 
345.975 
(3.696) 
332.220 
(3.152) 
.164 .001* .002* 
Right 
CA2/CA3 
141.058 
(4.537) 
130.820 
(3.463) 
130.364 
(3.318) 
.008* .004* .845 
Right 
CA4/dentate 
gyrus 
637.047 
(13.346) 
612.613 
(9.891) 
609.538 
(9.415) 
.039 .016 .665 
Right 
stratum1  
600.885 
(13.449) 
574.455 
(9.790) 
566.987 
(9.280) 
.030 .004* .307 
Left CA1 740.695 
(13.785) 
719.692 
(7.872) 
703.014 
(6.853) 
.160 .009* .062 
Left 
Subiculum 
340.451 
(6.521) 
323.144 
(3.781) 
315.635 
(3.339) 
.012 .000* .068 
Left 
CA2/CA3 
145.447 
(4.039) 
141.553 
(2.859) 
136.290 
(2.691) 
.193 .005* .020 
Left 
CA4/dentate 
gyrus 
622.448 
(13.025) 
605.913 
(9.188) 
596.490 
(8.639) 
.174 .028 .198 
Left stratum1  555.080 
(12.186) 
537.542 
(8.016) 
523.159 
(7.385) 
.147 .007* .048 
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Genotype by Diagnosis Interaction 
We observed a significant diagnosis-by-genotype interactions were found in both 
hemispheres (p<0.01, corrected, Table 10). A significant interaction was found bilaterally 
for the subiculum and the stratum regions. 
TABLE 10: Interaction – diagnosis*genotype for right and left hippocampal subfield 
volume for rs2973155. Note: all data was co-varied for age, sex, and principal component 
analysis values. Phenotype = healthy control or probands, genotype = HZ-R, HET, or 
HZ-NR. *indicates p<0.01 for Bonferroni correction for multiple comparisons.1 stratum 
refers to stratum radiatum, stratum lacunosum, and stratum moleculare. 
 
  
 
 
 
 
 
F 
 
Post-hoc analysis showed that, the healthy controls with the HET genotype had 
significantly higher volume in the left stratum compared to probands with the same 
genotype (p<0.01, corrected, Figure 5C, Supplemental Table 5). Moreover, while no 
effects of genotype were found in the subiculum within healthy controls, probands with 
the HET genotype demonstrated significantly higher right subiculum volumes than 
probands with the HZ-NR genotype (p<0.01, corrected, Figure 5B, Supplemental Table 
6). Significant differences in probands were also observed in the left subiculum, with 
Right Hemisphere  
 p-value F  
CA1 .058 2.148 
Subiculum .001* 4.415 
CA2/CA3 .047 2.261 
CA4/Dentate gyrus .028 2.535 
Stratum3 .006* 3.289 
Left Hemisphere 
 p-value F  
CA1 .020 2.703 
Subiculum .006* 3.302 
CA2/CA3 .032 2.461 
CA4/Dentate gyrus .068 2.071 
Stratum3 .001* 4.458 
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individuals with the HZ-R genotype having higher left subiculum volumes than those 
with the HZ-NR genotype (p<0.01, corrected, Figure 5A).  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5: A. The genotype by diagnosis interaction on left subiculum volume for 
rs2973155. B. The genotype by diagnosis interaction on right subiculum volume for 
rs2973155. C. The genotype by diagnosis interaction on left stratum volume for 
rs2973155. Note: data was co-varied for age, sex, and principal component analysis 
values. T/T = HZ-R, T/C = HET, C/C = HZ-NR. *indicates p<0.01 for Bonferroni 
correction for multiple comparisons. 
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rs9922678 – GRIN2A (SNP5) 
Across all subjects, a significant main effect of genotype on subfield volume was 
found bilaterally for the CA1, subiculum, and stratum, as well as the left CA2/CA3 and 
CA4/DG (Table 10). For each of those regions, those with the HZ-R genotype had 
significantly lower volumes compared to individuals with the HZ-NR genotype (p<0.01, 
corrected). In addition, those with the HET genotype showed significantly lower left 
CA1, CA4/DG, and stratum volumes than those with the HZ-NR genotype (p<0.01, 
corrected).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	39 
TABLE 11: Main effect of genotype on right and left hippocampal subfield volume for 
rs9922678. Note: all data was co-varied for age, sex, and principal component analysis 
values. 1 = stratum radiatum, stratum lacunosum, and stratum moleculare. *indicates 
p<0.01 for Bonferroni correction for multiple comparisons. 
 
 
 Genotype by Diagnosis Interaction 
We observed a significant diagnosis-by-genotype interactions were found in both 
hemispheres (p<0.01, corrected, Table 12). Bilateral significant interactions were found 
for the CA1, CA4/DG, and stratum regions. In addition, a significant interaction was 
found for the right subiculum. 
 
 
rs9922678 – SNP5 
 Mean Volume (mm3) [standard error] HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
HZ_R HET HZ_NR P value P value P value 
Right CA1 680.225 
(10.908) 
689.091 
(8.266) 
710.674 
(9.104) 
.402 .007* .014 
Right 
Subiculum 
328.253 
(4.906) 
339.467 
(3.252) 
348.803 
(3.818) 
.042 .000* .041 
Right 
CA2/CA3 
128.255 
(3.748) 
131.305 
(3.178) 
132.062 
(3.349) 
.300 .227 .757 
Right 
CA4/dentate 
gyrus 
603.267 
(11.108) 
608.878 
(9.386) 
623.917 
(9.903) 
.524 .029 .050 
Right 
Stratum1  
554.848 
(10.870) 
569.224 
(8.994) 
585.597 
(9.563) 
.113 .001* .026 
Left CA1 691.530 
(9.836) 
707.567 
(6.486) 
733.818 
(7.637) 
.148 .000* .004* 
Left 
Subiculum 
312.797 
(4.595) 
319.691 
(3.068) 
328.412 
(3.589) 
.178 .004* .041 
Left 
CA2/CA3 
133.995 
(3.325) 
138.773 
(2.727) 
142.267 
(2.909) 
.091 .006* .137 
Left 
CA4/dentate 
gyrus 
588.503 
(10.562) 
597.258 
(8.656) 
617.230 
(9.237) 
.330 .003* .008* 
Left Stratum1  511.533 
(9.514) 
527.094 
(7.372) 
548.754 
(8.044) 
.082 .000* .004* 
	40 
TABLE 12: Interaction – diagnosis*genotype for right and left hippocampal subfield 
volume for rs9922678. Note: all data was co-varied for age, sex, and principal component 
analysis values. Phenotype = healthy control or probands, genotype = HZ-R, HET, or 
HZ-NR. *indicates p<0.01 for Bonferroni correction for multiple comparisons.1 stratum 
refers to stratum radiatum, stratum lacunosum, and stratum moleculare. 
 
 
 
 
 
 
 
 
 
 
In addition, healthy controls with the HZ-R had significantly higher volume in the 
right CA4/DG and stratum than probands with the same genotype (p<0.01, corrected, 
Figure 6, see Supplemental Table 7). Furthermore, healthy controls with the HZ-NR 
genotype had significantly higher volume in the left stratum compared to probands 
(p<0.01, corrected). Moreover, while genotype in probands did not affect stratum 
volume, healthy controls with the HZ-R genotype had smaller bilateral CA1, CA4/DG, 
and stratum volumes than those with the HZ-NR genotype (p<0.01, corrected, Figure 6, 
see Supplemental Table 8).  
 
 
Right Hemisphere  
 p-value F  
CA1 .007* 3.206 
Subiculum .002* 3.767 
CA2/CA3 .120 1.757 
CA4/Dentate gyrus .003* 3.689 
Stratum3 .000* 4.581 
Left Hemisphere 
 p-value F  
CA1 .001* 4.027 
Subiculum .100 1.859 
CA2/CA3 .085 1.945 
CA4/Dentate gyrus .004* 3.512 
Stratum3 .000* 5.975 
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FIGURE 6: A. The genotype by diagnosis interaction on left CA4/DG volume for 
rs9922678. B. The genotype by diagnosis interaction on right CA4/DG volume for 
rs9922678. C. The genotype by diagnosis interaction on left stratum volume for 
rs9922678. D. The genotype by diagnosis interaction on right stratum volume for 
rs9922678. Note: data was co-varied for age, sex, and principal component analysis 
values. T/T = HZ-R, T/C = HET, C/C = HZ-NR. *indicates p<0.01 for Bonferroni 
correction for multiple comparisons. 
 
Polygenic Risk Score Results 
A polygenic risk score (PGRS) was generated using all six SNPs. Each participant 
was assigned a PGRS (for details, see “Methods”). The effect of PGRS on hippocampal 
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Polygenic Risk Score Results  
A polygenic risk score (PGRS) was generated using all six SNPs. Each participant 
was assigned a PGRS (for details, see “Methods”). The effect of PGRS on hippocampal 
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total volume and hippocampal subfield volume, again separated into right and left 
hemispheres, was examined.  
 Left Hemisphere 
 PGRS had a significant effect on left subiculum volume (Table 13). Individuals 
with a higher PGRS had a significantly lower left subiculum volume (p=0.0068, 
uncorrected, Figure 6), a finding that survived multiple comparisons (p<0.008, 
Bonferroni corrected). No interaction of PGRS*genotype was present. 
TABLE 13: Main effect of PGRS on left hippocampal total and subfield volume. Note: 
all data was co-varied for age, sex, and principal component analysis values. *indicates 
p<0.008 for Bonferroni correction for multiple comparisons.1 stratum refers to stratum 
radiatum, stratum lacunosum, and stratum moleculare. 
 
Left Hemisphere ALL SUBJECTS HEALTHY CONTROLS PROBANDS 
Region  Df T-value p-value Df T-value p-value Df T-value p-value 
Total 552 -1.88186 0.0604 268 -1.67258 0.0956 273 0.03778 0.9699 
CA1 552 -1.29887 0.1945 268 -1.20337   0.2299 273 0.31564  0.7525 
SB 552 -2.71702 0.0068* 268 -1.82748   0.0687 273 -1.81811   0.0701 
CA2_CA3 552 -1.17031 0.2424 268 -1.329794   0.1847 273 0.309279   0.7573 
CA4_DG 552 -1.42290 0.1553 268 -1.26662   0.2064 273 0.15020   0.8807 
STRATUM1 552 -1.67650 0.0942 268 -1.75405   0.0806 273 0.68591   0.4934 
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FIGURE 7: The effect of PGRS on left subiculum volume for all subjects. Note: data 
was co-varied for age, sex, and principal component analysis values.  
 
Right Hemisphere 
 PGRS also had a significant effect on right subiculum volume (Table 14), with 
individuals with a higher PGRS score having lower right subiculum volumes (p=0.0079, 
uncorrected, Figure 7). This finding also survived for multiple comparisons (p<0.008, 
Bonferroni corrected). No interaction of PGRS*genotype was present. 
 
 
 
 
-0.03 
-0.02 
-0.01 
0
0.01
0.02
0.03
0.04
200 250 300 350 400 450 500
Po
lyg
en
ic 
Ri
sk
 Sc
ore
Volume (mm3)
Polygenic Risk Score and Left Subiculum Volume
All Subjects
	44 
TABLE 14: Main effect of PGRS on right hippocampal total and subfield volume. Note: 
all data was co-varied for age, sex, and principal component analysis values. *indicates 
p<0.008 for Bonferroni correction for multiple comparisons.1 stratum refers to stratum 
radiatum, stratum lacunosum, and stratum moleculare. 
 
 
  
FIGURE 8: The effect of PGRS on right subiculum volume for all subjects. Note: data 
was co-varied for age, sex, and principal component analysis values.  
  
Right 
Hemisphere 
ALL SUBJECTS HEALTHY 
CONTROLS 
PROBANDS 
Region Df T-value p-value Df T-value p-
value 
Df T-value p-
value 
Total 552 -0.83785 0.4025 268  -0.38701   0.6991 273   
0.32333   
0.7467 
CA1 552 -0.57754 0.5638 268 -0.77911  0.4366 273 0.91010  0.3636 
SB 552 -2.66654 0.0079* 268 -1.59212 0.1125 273 -
1.75049   
0.0812 
CA2_CA3 552 0.60991 0.5422 268 0.984771   0.3256 273 0.51493
5   
0.6070 
CA4_DG 552 -0.05143 0.9590 268 0.41490   0.6785 273 0.65609   0.5123 
STRATUM1 552 -0.70631 0.4803 268 -0.17652   0.8600 273 0.33821   0.7355 
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DISCUSSION 
 
 This study examined the effects of genome-wide associated SNPs on bilateral 
hippocampal total volume and hippocampal subfield volumes in patients with 
schizophrenia/schizoaffective disorder and healthy controls. These SNPs met genome-
wide significance for schizophrenia in a sample of 36,989 probands and 113,075 healthy 
controls (Ripke et al., 2014). Of the 108 loci GWAS-identified SNPs, six of them were 
clearly implicated in glutamate metabolism and synaptic function: CLCN3, GRIA1, 
GRM3, GRIN2A, SLC387A, and SRR (Ripke et al., 2014; Bustillo et al., 2017). Our 
study tested six SNPs that spanned across 5 of the above loci – the SNP identified for the 
SRR gene was unavailable in our genetic data, as was another SNP located on GRIA1. 
We theorized that, because of the important, multifaceted role of glutamate in the 
hippocampus, mutations in these SNPs could lead to reduced hippocampal volume, due 
to dysfunction in the glutamate pathway. This could perhaps be a potential mechanism 
for how these genes confer risk for schizophrenia.  
Three of the SNPs that we examined (rs10520163, rs2973155, and rs9922678) 
demonstrated significant effects on bilateral total hippocampal volume. These SNPs also 
demonstrated a significant diagnosis-by-genotype interaction, with both genotype and 
diagnosis effects being observed. An effect of diagnosis was observed for rs10520163 
amongst individuals with the HZ-R genotype, with probands showing significantly 
smaller volumes than controls with the same genotype. For rs10520163 and rs9922678, 
individuals with either a HZ-R or HET genotype had significantly smaller volumes than 
individuals with the HZ-NR genotype. However, for rs2973155, an opposite effect was 
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observed, with individuals HZ-R having higher volumes than those with the HZ-NR 
genotype. Further analysis showed both a genotype effect and a diagnosis effect for 
rs10520163 for the right hemisphere, while rs9922678 showed significant genotype 
effects bilaterally.  
These SNPs were then examined to determine their effect on bilateral subfield 
volume. All three SNPs showed a significant main effect on the bilateral subiculum, 
bilateral stratum, and the left CA1. Again, for rs10520163 and rs9922678, individuals 
with the HZ-R genotype demonstrated significantly lower subfield volumes than HZ-NR 
individuals. Conversely, rs2973155 showed that individuals with the HZ-R genotype had 
higher subfield volumes than those with the HZ-NR genotype. Significant diagnosis-by-
genotype interactions were found for all three SNPs in the right subiculum and bilateral 
stratum. Both genotype and diagnosis effects were observed for all three SNPs.  
 
rs10520163 (CLCN3) – SNP1 
 CLCN3 is a gene on chromosome 4 that encodes a member of the voltage-gated 
chloride channel family (Borsani, Rugarli, Taglialatela, Wong, & Ballabio, 1995). This 
channel has been identified in glutamatergic synapses in the hippocampus and is thought 
to play a role in plasticity (Ripke et al., 2014). Studies of its murine analog, Clcn3, have 
suggested the importance of the channel in the hippocampus. In a study conducted in 
2002, mice lacking the chloride channels encoded by Clcn3 demonstrated 
neurodegeneration of the hippocampal formation (Dickerson et al., 2002). In particular, 
subregions including the DG, CA3, and CA1 showed significant hippocampal neuronal 
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loss (Dickerson et al., 2002).  These findings match a study conducted a year earlier in 
2001 where mice lacking the same channel demonstrated hippocampal degeneration, 
particularly a loss of pyramidal cells in the CA1 region (Stobrawa et al., 2001).  
Our study examined the SNP rs10520163, an intronic SNP located in the CLCN3 
gene, identified in the PGC GWAS (Ripke et al., 2014). Our findings were in line with 
findings from previous studies. Individuals HZ-R (T/T) showed decreased bilateral total 
hippocampal volume compared to those HZ-NR (C/C). While the decrease in volume 
observed could suggest neurodegeneration, further research would be needed in order to 
ascertain the specific cause of volume loss. However, our findings do suggest a role of 
illness, since healthy controls with the HZ-R (T/T) genotype demonstrated significantly 
higher volumes than probands of the same genotype. When examining the subfields, our 
results also showed a decrease in volume in the same subfields as previous studies, 
including in the right CA4/DG and the left CA1. These subfield results further suggest an 
effect of illness, with healthy controls having significantly higher volumes than probands, 
regardless of genotype.  
 
rs2973155 (GRIA1) – SNP2  
 GRIA1 , located on chromosome 5, encodes the GluR1 subunit of AMPA 
receptors (Ripke et al., 2014). Found primarily in the hippocampus and forebrain, GRIA1 
has been shown to play a role in several memory functions, including working memory 
and spatial memory tasks (Crisafulli et al., 2012). Previous studies have shown 
conflicting results on the association between certain GRIA1 SNPs and schizophrenia. 
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Studies have shown that certain GRIA1 SNPs are associated with increased risk of 
schizophrenia (Kang et al., 2012), while other studies have demonstrated significant 
differences in allele frequencies of these SNPs between healthy controls and probands 
(Magri et al., 2006). However, other work has shown no significant associations between 
these GRIA1 SNPs and schizophrenia (Crisafulli et al., 2012; Leon et al., 2011).  
It is important to note that these studies examined different variants of GRIA1, with 
parituclar emphasis on rs707176. In addition, these variants were examined between 
different ethnically homogenous populations (i.e. Italian vs. Korean populations). 
Furthermore, neither of these studies examined the SNP identified in the PGC GWAS, 
rs2973155. Our findings showed those with the HZ-R (T/T) genotype were found to have 
higher volumes than those HZ-NR (C/C), the opposite trend found in rs10520163 and 
rs9922678. This trend was also present when examining hippocampal subfields, with a 
pronounced effect of genotype within probands.   
A lack of AMPA receptor function usually leads to dysfunction in hippocampus-
relevant tasks. For instance, several studies have demonstrated that mice without the 
GluR1 subunit demonstrate spatial working memory deficits (Zamanillo et al., 1999; 
Reisel et al., 2002; Schmitt et al., 2004; Sanderson et al., 2007). Other knockout mice 
studies have indicated that a lack of GRIA1 leads to other behavior endophenotypes of 
schizophrenia including local hyperactivity and abnormal social behaviors (Wiedholz et 
al., 2008). While our study did not look at a lack of the AMPA receptor as a whole, there 
is still the potential that a single polymorphism inside the gene can cause dysfunction.  
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A general dysfunction of AMPA receptors has been associated with dysregulated 
synaptic strengthening (Stahl, 2007). Over time, this effect can lead to more pathological 
processes, such as inefficient glutamatergic transmission (Stahl, 2007). In a study 
conducted in 2005, elderly patients with schizophrenia demonstrated an increased level of 
mRNA for the GluR1 receptor (Dracheva, McGurk, & Harutunian, 2005). In another 
post-mortem study, increased levels of mRNA expression were again present for the 
GluR1 subunit were found in pyramidal brain cell (O’Connor & Hemby, 2007). A future 
course of study would be to examine when this increase in GluR1 receptors occurs, as 
well as whether this increase in GluR1 receptors is correlated with reduced hippocampal 
volume. If this increase occurs later in life and is indeed, correlated with reduced volume, 
our current participants would not be old enough to demonstrate this finding.  
 
rs9922678 (GRIN2A) – SNP5  
 GRIN2A is a candidate gene for schizophrenia that encodes the NMDA receptor 
subunit 2A (NR2A), whose expression does not occur until puberty (Tang et al., 2006). 
Mice without the mucine ortholog for GRIN2A have been shown to demonstrate both 
positive and negative symptoms of schizophrenia (Miyamoto et al., 2001). Before the 
PGC GWAS, much attention was dedicated to a particular repeat sequence of GRIN2A, 
known as the (GT)n repeat (Itokawa et al., 2003). Several studies have shown an 
association between the repeat polymorphism and schizophrenia (Iwayama-Shigeno et 
al., 2005; Itokawa et al., 2003; Tang et al., 2006). Furthermore, this larger numbers of 
this repeat have been associated with decreased hippocampal and amygdala volume 
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(Inoue et al., 2010). These findings implicate the role of GRIN2A in schizophrenia, and 
more importantly, suggest a relationship between this specific GRIN2A polymorphism 
and hippocampal volume. With the new PGC GWAS data, it was reasonable to look for a 
similar relationship to hippocampal volume with the new SNP identified.  
 While other studies have extensively examined the GT(n) repeat, fewer studies 
have looked at rs9922678. Of the literature that is present, one study did examine the 
effect of rs9922678 by incorporating it into a polygenic risk score. This study, conducted 
in 2017, created a glutamate-specific PGRS comprised of 3 of the SNPs from the PGC 
GWAS and looked for correlations between score and cognition in healthy controls 
(Rampino et al., 2017).  It is important to note that while this study did examine some of 
the same SNPs as ours, it looked at correlations with cognitive measures instead of 
anatomical brain volumes. Furthermore, it only examined these effects in healthy 
controls. To our knowledge, no other study has investigated the effect of this SNP on 
hippocampal volume in patients with schizophrenia. Our results are aligned with our 
hypothesis; individuals homozygous for the risk allele demonstrated significantly 
decreased volumes in both total and subfield hippocampal volume. Our study supports 
the proposed function of GRIN2A as a gene related to schizophrenia pathology, but 
further research on this newly discovered SNP will help to define its role more clearly.  
 
Polygenic Risk Score (PGRS) 
 The PGRS generated in this study was formed from the original six different 
glutamate-relevant SNPs chosen for the study. It is important to note again that these 
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SNPs met genome-wide significance in a large sample size (Ripke et al., 2014) and are 
located on the loci whose genes directly affect the glutamatergic process in the brain 
(Bustillo et al., 2017). PGRS was found to have a significant effect bilaterally on the 
subiculum. This effect was not evident in any other subfield of the hippocampus, nor was 
it associated with total right or left hippocampal volume. The subiculum can be 
considered a major synaptic relay for most CA1 neurons and is also thought to mediate 
hippocampal-cortical interaction with sources such as the entorhinal and perirhinal 
cortices (Francis et al., 2013). Furthermore, the subiculum is considered to be separated 
into dorsal and ventral sides, with the dorsal portion associated with space and memory 
and the ventral portion connected to the hypothalamic-pituitary-adrenal (HPA) axis 
(O’Mara, Sanchez-Vives, Brotons-Mas, & O’Hare, 2009). The dorsal and ventral 
subiculum are responsible for functions that are often affected in schizophrenia, such as 
declarative and verbal memory (Francis et al., 2013). In a study conducted in 2013, 
bilateral reduction of subicular volume was observed in patients at familial high risk for 
schizophrenia (Francis et al., 2013). Furthermore, reduction in volume was associated 
with poorer indices of verbal declarative memory. Our findings are in agreement with this 
study, highlighting the importance of the subiculum across the schizophrenia spectrum 
and its potential connection with certain genetic risks.  
To our knowledge, only one other study has created a PGRS using only glutamate 
relevant SNPs (Rampino et al., 2017). As described above, this study attempted to elicit a 
relationship between a score generated from potentially pathological risk variants and 
cognition in healthy controls (Rampino et al., 2017). Our study overlapped with three of 
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their SNPs, with our study excluding their fourth SNP (rs4523957, in the SRR gene). 
This group found an association between certain cognitive functions and PGRS, however, 
the study did not look at effects in patients with schizophrenia or schizoaffective and did 
not examine anatomical brain volumes. Future studies should examine both the effects of 
PGRS on anatomical brain measures as well as cognitive measures in patients, as 
dysfunction in both of these areas have been consistently identified in schizophrenia.  
 
Limitations   
 It is important to note several limitations for the present study. First, although the 
six SNPs selected for testing are directly related to glutamatergic processes, there are 
additional SNPs that may play a role in these processes, though as stated in Bustillo et al. 
(2017), they most likely have a more indirect role. With the popularity of the GWAS 
approach, several other large studies (Goes et al., 2015; Ripke et al., 2011; Athanasiu et 
al., 2010; Bergen & Petryshen, 2012) that have identified additional potential loci 
implicated in schizophrenia pathology. It would be of interest to investigate whether there 
are other glutamate-relevant SNPs related to genetic risk of schizophrenia, and to 
incorporate them into a new PGRS and examine its effect on hippocampal volume.  
In addition, the role of medication on brain volume has been extensively 
investigated, but findings have been mixed. It is clear, however, that medication has some 
effect on brain volume and therefore, finding a way to account for duration of medication 
is paramount. Furthermore, all data was gathered at one time point. As discussed for 
rs2973155, some pathological effects associated with certain genes are not discovered 
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until later in age, and therefore, a longitudinal study may be more helpful in ascertaining 
more specific roles for these genes. In addition, as significant effects of age and gender 
were found, it would be ideal to test the effect of these SNPs in a more homogenous 
population, matched for age and sex. It is also important to mention that many genetic 
studies have much larger population studies and as such, replication in a larger sample 
size would be desirable. Furthermore, though we used principal component analysis in an 
attempt to better account for race, our sample size was still composed of several different 
races. Despite using PCA values thought to equate for at least 75% of the variance as 
covariates, racial differences could still have an effect on results and should be taken into 
consideration in future studies.  
 The potential effects of environmental factors should be taken into account. Gene-
environment interactions, while important, can be very hard to account for. While some 
factors, such as prenatal or obstetric complications, are easy to record, other factors, such 
as upbringing conditions are difficult to quantify. While research (Dean & Murray, 2005) 
is currently looking at various environmental factors that may play a role in 
schizophrenia (i.e. childhood factors, drug abuse or migration effects) further study is 
needed to find a way to explore these effects and how these variables may interact with 
genetics. 
 Finally, there is the matter of the common disease-common allele (CDCA) 
approach versus the common disease-rare allele (CDRA) method. The CDRA method 
emphasizes involvement of individually rare but highly penetrant alleles (Rodriguez-
Murillo et al., 2012), with the idea that disease is caused by a single very rare allele. As 
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the SNPs examined in this paper were those that met GWAS significance and were found 
in a large population sample, rare alleles were likely not taken into account. The role of 
these rare alleles must be examined in the future, both individually and in relationship to 
other rare and other common alleles.  
 
Future Directions  
 Future work will examine the role of rs10520163, rs2973155, and rs9922678 and 
their potential relationship to biotypes. Three new “biotypes” were outlined in a study 
conducted by Clementz et al., did not adhere to traditional DSM diagnosis boundaries 
(Clementz et al., 2016). These biotypes were created via integration of different 
biomarkers of psychosis in an attempt to better categorize and account for the large 
heterogeneity that is seen across psychotic disorders. The study demonstrated the 
effectiveness of classifying patients into biotypes based on neurobiological findings, as 
opposed to classical clinical diagnoses from the DSM (Clementz et al., 2016). As this 
study was conducted with data from the same B-SNIP consortium as ours, it would be 
important to examine the effects of different SNPs within biotype groups. Though 
biotypes were created using various neurobiological measures, it would be interesting to 
see whether or not genetics are connected, as genetics have been independently 
associated with several of the neurobiological measures used. The creation of these 
biotypes support the idea of psychosis subtypes and suggest that some subtypes having 
more genetic component, while others have a more environmental component. Therefore, 
this approach could be a potential way to incorporate the aforementioned environmental 
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factors that were not taken into account in this study. In addition, as several studies have 
associated either glutamatergic PGRS or measures of subicular volume with cognitive 
measures, it would be helpful for our study to also examine the relationship between our 
significant SNPs and cognition. Finally, it could be of interest to examine the effect of 
PGRS on hippocampal morphology, particularly in the subiculum. 
 
Conclusion  
 This study examined the effect of six glutamate-relevant SNPs that reached 
genome-wide significance (Ripke et al., 2014), on hippocampal volume. Three SNPs 
(rs10520163, rs2973155, and rs9922678) showed significant effects on hippocampal total 
and subfield volume, with particular emphasis on the subiculum. When incorporating all 
six SNPs into a polygenic risk score and examining its effects on hippocampal total and 
subfield volume, results suggest a cumulative effect of these glutamate-relevant SNPs on 
the subiculum. While future research is needed to further quantify the importance of these 
SNPs, this study supports the importance of glutamatergic function in the hippocampus 
of patients with schizophrenia and schizoaffective disorder and suggests a potential 
mechanism for how these common genetic variants may play a role in the disease 
pathology.	  
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APPENDIX 
 
SUPPLEMENTAL TABLE 1: The genotype by diagnosis interaction on right and left 
total hippocampal volume for all SNPs. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.016 for Bonferroni correction for 
multiple comparisons. 1indicates combined volume of CA1, subiculum, CA2/CA3, 
CA4/DG, and stratum. HZ-R = homozygous risk genotype. HET = heterozygous 
genotype. HZ-NR = homozygous-no risk genotype. 
 
Right Hemisphere 
 HZ_R – Total Volume1 (mm3) 
[standard error] 
HET – Total Volume1 (mm3) 
[standard error] 
HZ_NR – Total Volume1  (mm3) 
[standard error] 
 Control Proband p-value Control Proband p-value Control Proband p-
value 
SNP1 
rs10520163 
2366.164 
(36.683) 
2269.476 
(33.921) 
.014* 2353.219 
(32.612) 
2346.922 
(33.205) 
.856 2463.382 
(41.123) 
2344.161 
(47.401) 
.028 
SNP2 
rs2973155 
2478.597 
(53.281) 
2421.226 
(61.610) 
.449 2392.445 
(34.638) 
2323.861 
(34.628) 
.078 2351.567 
(31.169) 
2298.954 
(30.986) 
.104 
SNP3 
rs12522290 
2371.585 
(29.092) 
2300.728 
(29.360) 
.010* 2400.672 
(44.789) 
2368.167 
(42.711) 
.543 2489.310 
(106.338) 
2499.821 
(196.267) 
.962 
SNP4 
rs12704290 
2505.967 
(196.645) 
2423.275 
(277.395) 
.807 2366.868 
(48.336) 
2366.698 
(61.206) 
.998 2380.955 
(27.799) 
2307.325 
(27.563) 
.004* 
SNP5 
rs9922678 
2276.619 
(45.846) 
2301.767 
(39.860) 
.642 2374.123 
(30.717) 
2299.816 
(30.211) 
.027 2437.678 
(32.675) 
2346.102 
(36.547) 
.025 
SNP6 
rs12325245 
2391.226 
(27.944) 
2307.176 
(28.476) 
.003* 2412.678 
(41.784) 
2332.396 
(39.701) 
.109 2331.134 
(196.100) 
2423.128 
(106.107) 
.678 
Left Hemisphere 
 HZ_R – Total Volume1 (mm3) 
[standard error] 
HET – Total Volume1 (mm3) 
[standard error] 
HZ_NR – Total Volume1  (mm3) 
[standard error] 
 Control Proband p-value Control Proband p-value Control Proband p-
value 
SNP1 
rs10520163 
2304.993 
(34.287) 
2227.695 
(31.021) 
.054 2314.396 
(29.586) 
2305.370 
(30.244) 
.799 2422.524 
(39.166) 
2312.680 
(46.052) 
.048 
SNP2 
rs2973155 
2418.096 
(52.526) 
2380.991 
(61.529) 
.636 2368.618 
(31.772) 
2281.419 
(31.692) 
.030 2292.848 
(27.652) 
2254.193 
(27.278) 
.247 
SNP3 
rs12522290 
2324.735 
(25.124) 
2262.821 
(25.355) 
.027 2335.308 
(42.951) 
2321.697 
(40.597) 
.803 2347.553 
(107.690) 
2423.424 
(200.206) 
.583 
SNP4 
rs12704290 
2647.912 
(201.163) 
2254.733 
(284.240) 
.258 2344.151 
(46.844) 
2368.588 
(60.668) 
.742 2327.618 
(23.336) 
2263.929 
(22.916) 
.016 
SNP5 
rs9922678 
2229.729 
(44.733) 
2239.279 
(38.058) 
.864 2319.208 
(27.792) 
2258.861 
(27.126) 
.079 2400.936 
(30.102) 
2322.709 
(34.445) 
.063 
SNP6 
rs12325245 
2349.889 
(23.670) 
2272.744 
(24.130) 
.008* 2338.827 
(39.688) 
2270.662 
(37.477) 
.187 2252.047 
(201.663) 
2384.226 
(108.270) 
.563 
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SUPPLEMENTAL TABLE 2: The genotype by diagnosis interaction on right and left 
total hippocampal volume for all SNPs. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.008 for Bonferroni correction for 
multiple comparisons. HZ-R = homozygous risk genotype. HET = heterozygous 
genotype. HZ-NR = homozygous-no risk genotype. 
 
 
 
 
 
 
 
RIGHT HEMISPHERE 
  
HEALTHY CONTROLS 
  
PROBANDS 
 HZ_R 
vs. HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
SNP1 
rs10520163 
.733 .032 .009* .028 .126 .955 
SNP2 
rs2973155 
.126 .019 .256 .127 .050 .484 
SNP3 
rs12522290 
.504 .267 .426 .101 .310 .507 
SNP4 
rs12704290 
.488 .525 .766 .841 .676 .326 
SNP5 
rs9922678 
.043 .001* .075 .962 .340 .229 
SNP6 
rs12325245 
.604 .759 .682 .523 .276 .408 
 
 
LEFT HEMISPHERE 
  
HEALTHY CONTROLS 
  
PROBANDS 
 HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
SNP1 
rs10520163 
.809 .012 .012 .032 .090 .883 
SNP2 
rs2973155 
.395 .025 .042 .132 .049 .458 
SNP3 
rs12522290 
.812 .040 .063 .162 .424 .616 
SNP4 
rs12704290 
.140 .113 .734 .695 .974 .092 
SNP5 
rs9922678 
.071 .001* .026 .646 .081 .108 
SNP6 
rs12325245 
.795 .629 .672 .959 .310 .316 
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SUPPLEMENTAL TABLE 3: The genotype by diagnosis interaction on right and left 
hippocampal subfield volume for rs10520163. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.01 for Bonferroni correction for 
multiple comparisons. 
 
SNP1 
 Mean Volume (mm3) [standard error] 
Homozygous – Risk  Heterozygous Homozygous – NoRisk 
Control Proband p-
value 
Control Proband p-
value 
Control Proband p-
value 
Right CA1 692.612 
(11.730) 
672.180 
(10.732) 
.120 697.181 
(10.274) 
695.065 
(10.483) 
.856 727.208 
(13.281) 
691.319 
(15.469) 
.049 
Right Subiculum 331.680 
(5.344) 
326.779 
(4.697) 
.469 346.195 
(4.454) 
340.497 
(4.566) 
.342 365.355 
(6.204) 
344.512 
(7.434) 
.208 
Right 
CA4/Dentate 
gyrus 
624.543 
(11.447) 
594.510 
(10.778) 
.006* 610.957 
(10.447) 
609.378 
(10.596) 
.870 638.239 
(12.580) 
616.280 
(14.196) 
.146 
Right stratum  579.430 
(11.326) 
548.450 
(10.611) 
.006* 572.578 
(10.261) 
572.546 
(11.631) 
.997 607.349 
(12.521) 
566.325 
(15.220) 
.008* 
Left CA1 712.354 
(10.934) 
688.067 
(9.668) 
.076 714.588 
(9.174) 
713.199 
(9.403) 
.909 752.433 
(12.660) 
715.466 
(15.119) 
.052 
Left Subiculum 313.202 
(5.155) 
313.411 
(4.585) 
.974 323.546 
(4.355) 
323.573 
(4.462) 
.996 330.751 
(5.952) 
326.964 
(7.083) 
.667 
Left CA4/Dentate 
gyrus 
605.411 
(11.046) 
582.095 
(10.308) 
.037 602.376 
(9.950) 
604.557 
(10.111) 
.826 625.449 
(12.266) 
609.879 
(13.996) 
.314 
Left stratum  531.398 
(9.989) 
510.195 
(9.171) 
.055 537.867 
(8.791) 
525.472 
(8.964) 
.204 569.592 
(11.275) 
525.593 
(13.089) 
.004* 
 
 
SUPPLEMENTAL TABLE 4: The genotype by diagnosis interaction on right and left 
hippocampal subfield volume for rs10520163. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.01 for Bonferroni correction for 
multiple comparisons. HZ-R = homozygous risk genotype. HET = heterozygous 
genotype. HZ-NR = homozygous-no risk genotype. 
 
 
 
 
 
 
 
 
 
 
 
SNP1 
 HEALTHY CONTROLS  PROBANDS 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
Right CA1 .721 .024 .034 .054 .243 .819 
Right Subiculum .028 .002* .164 .025 .037 .634 
Right CA2/CA3 .003* .618 .032 .771 .572 .436 
Right CA4/dentate 
gyrus 
.200 .280 .020 .131 .110 .611 
Right Stratum  .528 .032 .004* .017 .200 .654 
Left CA1 .867 .012 .010 .042 .109 .894 
Left Subiculum .095 .018 .292 .077 .088 .668 
Left CA2/CA3 .103 .492 .027 .176 .866 .415 
Left CA4/dentate 
gyrus 
.780 .123 .055 .026 .047 .702 
Left Stratum  .546 .003* .007* .125 .263 .993 
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SUPPLEMENTAL TABLE 5: The genotype by diagnosis interaction on right and left 
hippocampal subfield volume for rs2973155. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.01 for Bonferroni correction for 
multiple comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP2 
 Mean Volume (mm3) [standard error] 
Homozygous – Risk  Heterozygous Homozygous – NoRisk 
Control Proband p-value Control Proband p-value Control Proband p-value 
Right CA1 732.456 
(17.509) 
707.776 
(20.347) 
.331 705.513 
(11.080) 
687.568 
(11.070) 
.168 693.046 
(9.855) 
681.567 
(9.777) 
.289 
Right Subiculum 359.399 
(8.655) 
352.719 
(10.226) 
.616 346.144 
(4.957) 
345.884 
(4.921) 
.970 338.685 
(4.182) 
326.300 
(4.062) 
.028 
Right CA4/Dentate gyrus 646.621 
(15.755) 
623.089 
(17.965) 
.266 624.658 
(10.969) 
600.054 
(10.973) 
.024 612.749 
(10.126) 
606.404 
(10.097) 
.483 
Right stratum  604.158 
(15.849) 
595.869 
(18.166) 
.703 584.978 
(10.769) 
563.145 
(10.772) 
.051 576.132 
(9.858) 
557.658 
(9.822) 
.044 
Left CA1 742.868 
(17.574) 
736.746 
(20.720) 
.819 732.943 
(10.250) 
706.143 
(10.196) 
.051 709.764 
(8.740) 
696.540 
(8.547) 
.245 
Left Subiculum 335.045 
(8.211) 
348.103 
(9.634) 
.289 322.785 
(4.922) 
323.502 
(4.907) 
.910 317.541 
(4.263) 
313.813 
(4.198) 
.477 
Left CA4/Dentate gyrus 625.880 
(15.712) 
617.061 
(18.064) 
.686 617.855 
(10.517) 
593.640 
(10.518) 
.031 598.122 
(9.573) 
594.915 
(9.532) 
.731 
Left stratum  566.931 
(14.712) 
537.688 
(17.148) 
.175 552.995 
(9.156) 
521.072 
(9.144) 
.004* 530.914 
(8.082) 
515.324 
(8.004) 
.090 
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SUPPLEMENTAL TABLE 6: The genotype by diagnosis interaction on right and left 
hippocampal subfield volume for rs2973155. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.01 for Bonferroni correction for 
multiple comparisons. HZ-R = homozygous risk genotype. HET = heterozygous 
genotype. HZ-NR = homozygous-no risk genotype. 
 
SUPPLEMENTAL TABLE 7: The genotype by diagnosis interaction on right and left 
hippocampal subfield volume for rs9922678. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.01 for Bonferroni correction for 
multiple comparisons. 
 
SNP5 
 Mean Volume (mm3) [standard error] 
Homozygous – Risk  Heterozygous Homozygous – NoRisk 
Control Proband P 
value 
Control Proband P 
value 
Control Proband P 
value 
Right CA1 672.617 
(15.088) 
684.908 
(13.002) 
.500 698.208 
(9.800) 
680.271 
(9.613) 
.112 721.942 
(10.499) 
694.750 
(11.854) 
.048 
Right 
Subiculum 
337.748 
(7.422) 
321.659 
(6.234) 
.090 338.769 
(4.415) 
340.053 
(4.280) 
.825 354.262 
(4.840) 
341.292 
(5.608) 
.069 
Right 
CA4/Dentate 
gyrus 
592.910 
(13.872) 
609.664 
(12.367) 
.267 622.455 
(10.115) 
595.774 
(10.004) 
.004* 631.738 
(10.577) 
612.544 
(11.529) 
.092 
Right stratum  550.557 
(13.734) 
556.859 
(12.110) 
.685 581.024 
(9.656) 
557.602 
(9.530) 
.015 597.397 
(10.168) 
569.481 
(11.207) 
.017 
Left CA1 691.309 
(14.823) 
691.069 
(12.377) 
.990 715.236 
(8.654) 
700.129 
(8.353) 
.197 745.317 
(9.541) 
717.602 
(11.109) 
.054 
Left 
Subiculum 
314.457 
(6.953) 
311.670 
(5.842) 
.753 318.774 
(4.142) 
320.550 
(4.142) 
.744 329.896 
(4.539) 
326.417 
(5.256) 
.602 
Left 
CA4/Dentate 
gyrus 
579.019 
(13.697) 
594.522 
(12.081) 
.316 607.786 
(9.640) 
587.139 
(9.515) 
.031 621.406 
(10.150) 
611.017 
(11.183) 
.373 
Left stratum  512.460 
(12.669) 
509.708 
(10.914) 
.857 537.989 
(8.219) 
516.118 
(8.061) 
.021 561.665 
(8.807) 
530.103 
(9.948) 
.006* 
 
SNP2 
 HEALTHY CONTROLS  PROBANDS 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
Right CA1 .153 .030 .301 .344 .208 .614 
Right Subiculum .179 .029 .238 .543 .016 .002* 
Right CA2/CA3 .233 .188 .913 .009* .006* .889 
Right CA4/dentate 
gyrus 
.162 .025 .236 .196 .337 .524 
Right Stratum  .235 .074 .408 .074 .033 .592 
Left CA1 .617 .083 .069 .176 .067 .443 
Left Subiculum .180 .046 .370 .018 .001* .093 
Left CA2/CA3 .367 .025 .050 .412 .114 .198 
Left CA4/dentate 
gyrus 
.621 .075 .057 .203 .217 .901 
Left Stratum  .384 .019 .031 .360 .206 .570 
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SUPPLEMENTAL TABLE 8: The genotype by diagnosis interaction on right and left 
hippocampal subfield volume for rs9922678. Note: data was co-varied for age, sex, and 
principal component analysis values. *indicates p<0.01 for Bonferroni correction for 
multiple comparisons. HZ-R = homozygous risk genotype. HET = heterozygous 
genotype. HZ-NR = homozygous-no risk genotype. 
 
SNP5 
 HEALTHY CONTROLS  PROBANDS 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
HZ_R vs. 
HET 
HZ_R vs. 
HZ_NR 
HET vs. 
HZ_NR 
Right CA1 .114 .003* .049 .740 .529 .265 
Right Subiculum .903 .056 .013 .012 .016 .854 
Right CA2/CA3 .020 .041 .763 .468 .788 .648 
Right CA4/dentate 
gyrus 
.028 .005* .351 .231 .824 .119 
Right Stratum  .027 .001* .110 .950 .344 .282 
Left CA1 .158 .002* .017 .536 .106 .199 
Left Subiculum .583 .057 .057 .191 .053 .353 
Left CA2/CA3 .164 .019 .174 .328 .194 .607 
Left CA4/dentate 
gyrus 
.037 .003* .182 .534 .215 .030 
Left Stratum  .061 .000* .019 .585 .121 .200 
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